Kampala, Uganda | URN | The Uganda Cancer Institute (UCI) has raised concern over the high rate of late prostate cancer diagnosis in the country, revealing that up to 80 per cent of patients arrive at specialised treatment centres when the disease has already advanced to stages three and four.
According to the institute, an estimated 2,537 Ugandan men are diagnosed with prostate cancer annually, making it one of the leading causes of cancer-related illness and death among men in the country.
As Uganda joins the rest of the world to mark Prostate Cancer Awareness Month in November, Dr Alfred Jatho, Head of Community Cancer Services at UCI, has called for intensified awareness campaigns, increased screening uptake and the decentralisation of diagnostic and treatment services to improve early detection.
Speaking to journalists at the Uganda Media Centre on Wednesday, Dr Jatho attributed the high rate of late diagnosis to low screening uptake, stigma, misconceptions about the disease and limited diagnostic capacity in rural health facilities.
He warned that the situation could worsen as Uganda’s population grows and life expectancy increases, noting that the risk of developing prostate cancer rises with age.
“Prostate cancer is highly curable when detected early. However, many patients come when the disease is already advanced, when treatment may not necessarily cure them,” he said.
Dr Jatho urged men aged 40 and above to consult healthcare providers about prostate cancer screening, particularly those with a family history of the disease, who face an elevated risk.
He also called on communities to challenge misconceptions linking prostate cancer to witchcraft, having multiple sexual partners or abstaining from sexual intercourse, describing such beliefs as barriers to timely medical attention.
The UCI official further cautioned against relying on unapproved herbal medicines and plant-based products marketed as cancer prevention or treatment remedies.
He explained that although research is emerging on the potential benefits of some herbal products, most have not undergone sufficient scientific investigation and clinical trials to establish their safety and effectiveness. He said the available evidence is not strong enough for UCI or the government to recommend such products as established cancer treatments.
On concerns about exposure to pesticides, Dr Jatho acknowledged that prolonged exposure to certain chemicals may increase the risk of some cancers, although pesticides are not among the strongest established risk factors for prostate cancer.
He also addressed claims that frequent ejaculation may help prevent prostate cancer, noting that some observational studies have suggested a possible association between ejaculation frequency and reduced prostate cancer risk.
However, he cautioned that the findings have not translated into an established clinical recommendation for preventing the disease.
“Where it is difficult to conduct clinical trials, researchers rely on observational studies. But we cannot recommend something at hospital level without an established protocol,” he explained.
Dr Jatho also highlighted the impact of prostate cancer and its treatment on men’s sexual health, noting that the disease itself can affect sexual function even before treatment begins.
He explained that treatment options, including surgery to remove the prostate gland, may also affect a man’s ability to achieve an erection or ejaculate. However, early diagnosis can widen treatment options and, in suitable cases, allow specialists to use approaches that preserve surrounding healthy tissue and nerves.
He emphasised that the possibility of maintaining sexual function depends on the stage of the cancer, the extent of its spread and the treatment approach recommended by specialists.
Dr Jatho urged men to take advantage of available screening opportunities rather than wait for symptoms to develop, stressing that early detection improves treatment prospects, expands available options and reduces complications associated with advanced disease.



